Ensifentrine
An inhaled PDE3/PDE4 inhibitor for COPD.
Key point
Ensifentrine significantly improved lung function, symptoms and quality of life versus placebo in Chinese individuals with COPD, with similar adverse event rates.
From: Efficacy and Safety of Ensifentrine in Chinese Participants With COPD: The ENHANCE-CHINA Randomized Clinical Trial (Chest, 2026 Jul) ↗Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 1, 2, 2, 2, 1.
All papers from the last 12 months
25 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Ensifentrine inhibits lipopolysaccharide-induced production of cytokines by human lung macrophages: a comparison with roflumilast, and an interaction with adenosineInt Immunopharmacol2026 Oct 16PMID 42887045
- Natural PDE4 inhibitors from plants: A comprehensive review of discovery, structure-activity relationships, and clinical translation potentialEur J Med Chem2026 Oct 5PMID 42166818Review
- Updates in COPD Management: From Inflammatory Pathways to Targeted TherapiesEur J Clin Invest2026 OctPMID 42773542Review
- Post-marketing safety of ensifentrine in COPD: A retrospective pharmacovigilance study using disproportionality analysis of FAERS/AEMS reportsMedicine (Baltimore)2026 Sep 25PMID 42798039
- Integrating Disease Burden and Cost-Effectiveness for Value-Based Prioritisation of COPD Interventions: A Narrative ReviewInt J Chron Obstruct Pulmon Dis2026PMID 42761905Review
- Bronchorelaxant and anti-inflammatory profile of ensifentrine alone and combined with inhaled medications in lipopolysaccharide-challenged human airways from chronic obstructive pulmonary disease donorsJ Pharmacol Exp Ther2026 AugPMID 42509122
- Low-dose ensifentrine exerts anti-inflammatory effects comparable to roflumilast in COPD airwaysAm J Respir Cell Mol Biol2026 Jul 25PMID 42503891
- The discovery and development of ensifentrine: A novel inhaled dual PDE3/4 inhibitor having 'bifunctional' bronchodilator and anti-inflammatory activityBr J Pharmacol2026 Jul 5PMID 42402420Review
- A Breath of Life Beyond Bronchodilation: Early Data on Hemodynamic and Functional Outcomes With Ensifentrine Nebulization in Severe COPD-associated Pulmonary HypertensionOpen Respir Med J2026PMID 42582753
- Efficacy and Safety of Ensifentrine in Chinese Participants With COPD: The ENHANCE-CHINA Randomized Clinical TrialChest2026 JulPMID 41895581RCT
More pulmonology trends
All specialties →Antifibrotics in pulmonary fibrosis
Nintedanib, pirfenidone and newer antifibrotics.
Biologics in severe asthma
Biologic therapies for severe asthma.
Key point: Biologic choice in adult severe asthma can be impacted by quality of life impairment, lung function, exacerbation frequency, oral corticosteroid use, endotype, biomarkers and comorbidities.
Lung cancer screening
Low-dose CT screening for lung cancer.
Key point: Low-dose CT screening reduces lung cancer death risk by at least 21% and should be offered to people aged 50–75 with at least 20 pack-years.
E-cigarettes and the lungs
Respiratory effects of vaping and e-cigarettes.
Sotatercept
An activin signalling inhibitor for pulmonary arterial hypertension.
Interstitial lung abnormalities
Incidental interstitial changes on CT and their significance.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
ensifentrine[tiab]Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.